Skip to main content
Download PDF
Download ePub

Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients

Pneumonia volume 16, Article number: 1 (2024) Cite this article

Abstract

Toll-like receptor 4 (TLR4) signaling mediates sustained systemic inflammation in(COVID)-19 patients. We aimed to assess the serum levels of sTLR4 and sCD14 as negative regulators of Toll like receptor signaling and their association with laboratory markers and clinical severity in covid 19 patients. Ninety-eight patients with COVID-19 (70 severe and 28 non-severe) were enrolled in the study. Serum sCD14 andsTLR4were determined by ELISA. A significant increase in serum sTLR4 and sCD14 levels was detected in severe compared to non severe COVID19 patients.Receiver operating characteristic curve (ROC) analysis revealed significant diagnostic potential of serum sTLR4 and sCD14 in covid19 patients.We conclude that Serum sTLR4 and sCD14 may be promising clinical severity markers for COVID19 patients.

Introduction

The coronavirus disease (COVID)-19 epidemic outbreak culminated in a global health disaster in 2020 [1]. The clinical symptoms of patients with COVID-19 range from mild (fever, cough, myalgia, sputum production, headache, hemoptysis, diarrhea and dyspnea) to severe lung inflammation, severe pneumonia and acute respiratory distress syndrome (ARDS) [2]. It can also potentially impact several organs in vulnerable people, causing cardiac and renal complications, as well as death [3]. Systemic inflammation in patients with COVID-19 is mediated by toll-like receptors (TLRs) and nod-like receptors, which are pattern recognition receptors expressed in a range of innate immune cells found in the alveolar milieu, including monocytes, macrophages and dendritic cells [4, 5]. TLR4 is an innate immune receptor which has the greatest affinity and protein interaction with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein, which promotes,excessive immune response, systemic inflammation, myocarditis,ARDS and damage to numerous organs in covid19 patients [6, 7]. TLR4 signaling is regulated dynamically to avoid chronic systemic inflammation and tissue damage. A variety of endogenous mechanisms negatively regulate TLR4 signaling, including cell membrane-bound TLR suppressors and soluble TLRs (sTLRs) [8]. Extracellular sTLRs function as decoy receptors, preventing ligand-induced signaling [9]. Soluble TLR4 (sTLR4) as decoy receptor and soluble CD14 (sCD14) as coreceptor for TLR4 receptor have been found to inhibit lipopolysaccharide (LPS)-induced nuclear factor-κB activation and TNF generation, [10, 11]. STLR4 inhibits TLR4-mediated signaling, possibly by interfering with receptor–ligand associations [10], While soluble CD14 is involved in regulating TLR4-induced cytokine release, via direct binding to LPS and altering the signaling patterns [12,13,14,15,16]. Collectively, we postulate that inhibiting TLR4 by endogenous negative regulators sTLR4 and sCD14 may improve patient outcomes by preventing systemic infection and dampening the inflammatory response in patients withCOVID-19. On this basis, the aim of the present study was to assess the serum levels of sTLR4 and sCD14 in patients with COVID-19,to examine their relationship with hematological abnormalities and to investigate their predictive value as a clinical severity marker for patients with COVID-19.

Patients and methods

Patients

In this cross-sectional study, 98 patients with nasopharyngeal swab reverse transcription-quantitative (RT-q) PCR-confirmed SARS-CoV-2 infection and without associated chronic disease were admitted to Mansoura university hospital COVID-19 isolation treatment center. The studied patients were selected from 300 patients admitted to the hospital from march 2020 to december 2020. None of the studied patients were assigned to any therapeutic regimens for COVID-19(such as systemic corticosteroids and hydroxychloroquine) before blood samples were taken. Patients were classified into two groups: Severe COVID-19 patients (SCP group;n = 70)and non-severeCOVID-19 patients (NSCP group;n = 28). Each individual enrolled in this study provided informed consent. The study was authorized by the Ethical Committee of the Faculty of Medicine of Mansoura University (approval no. R.21.9.1450; Egypt).

Patients were categorized according to the World Health Organization (WHO) severity definitions as follows: ARDS, sepsis, septic shock or other disorders that would usually necessitate the administration of life-sustaining therapies, such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy, severe COVID-19 is characterized as an oxygen saturation of < 90% on room air, a respiratory rate of > 30 breaths per minute in adults, or signs of significant respiratory distress in adults (such as accessory muscle use and inability to complete full sentences), as well as non-severe COVID-19, which is described as the absence of any serious or critical COVID-19 criteria(“COVID-19 Clinical Management: Living Guidance”, 2021).

Exclusion criteria

This study excluded patients with systemic chronic illnesses (such as hypertension, diabetes, chronic liver disease, malignancy or systemic autoimmune disease).

Methods

Blood sampling

A total of 10 ml whole venous blood was taken from each participant via venipuncture with sterile disposable plastic syringes and divided into three aliquots. For a full blood count (CBC), the initial aliquot of 2 ml was collected into blood collection tubes containing K2EDTA. The second 2.5 ml aliquot was collected into 3.2% sodium citrate anticoagulated tubes for prothrombin, international normalized ratio (INR) and D-dimer measurement. The third aliquot was collected in plain dry tubes and allowed to clot at room temperature for 30 min before being centrifuged at 4,000 rpm for 10 min to separate serum. The separated serum was divided into two aliquots: One was used for biochemical examinations of serum alanine aminotransferase (ALT) and aspartate transaminase (AST) activities, serum creatinine levels, serum ferritin, serumC-reactive protein (CRP) and serum lactate dehydrogenase (LDH), and the other was stored at -20˚C for determination of serum sTLR4 and sCD14 levels.

RT-qPCR detection of COVID-19

Polyester flocked swabs were used to collect throat and nasopharyngeal swabs from all suspected SARS-CoV-2-infected patients. SARS-CoV-2 RNA was detected using a fully automated QIAGEN QIAcube system (Qiagen, Inc.) via RT-qPCR.

Biochemical determination of serum sCD14 by ELISA

Serum sCD14 was detected by using a Human ELISA kit (cat. no. 201–12-0318) provided by Shanghai Sunred Biological Technology Co., Ltd.

Biochemical determination of serum sTLR4 by ELISA

Serum sTLR4 was assessed by using a Human ELISA kit (cat. no. 201–12-6874) provided by Shanghai Sunred Biological Technology Co., Ltd.

Statistical analysis

All statistical analyses were performed using SPSS for windows version 20.0 (IBM Corp.). Variables with continuous data were explored for normality of distribution using Kolmogorov–Smirnov test. The age variable was normally distributed and was expressed as the mean ± standard deviation (SD), while the other variables showed abnormal distribution of data and were expressed as the median and interquartile range (IQR). Categorical data were expressed as number and percentage. A Student’s t-test was used for comparisons between two groups of continuous data with normal distribution, while a Mann–Whitney U test was used for comparisons between two groups of abnormally distributed data. A Chi-square test was used for comparisons between groups of categorical data. A Pearson’s correlation test was used to determine the correlations between sCD14 and sTLR4 with other variables with continuous data. Receiver operating characteristic (ROC) curve analysis was performed to determine the ability of the serum sCD14 and sTLR4 levels to discriminate SCPs from NSCPs and the area under the curve (AUC) was determined. Binary regression analysis for factors predicting the severity of COVID-19 was also performed. P < 0.05 was considered to indicate a statistically significant difference.

Sample size

Based on data from literature (Rialet al., 2020) [17], considering level of significance of 5%, and power of study of 80%, the sample size was calculated using the following formula: Sample size = [(Z1-α/2)2.SD2]/d2, where, Z1-α/2 at 5% type 1 error (p < 0.05) is 1.96, SD = standard deviation of variable and d = absolute error or precision. So, Sample size = [(1.96)2.(1267.1)2]/(250.9)2 = 97.9. Based on the above formula, the sample size required for the study is 98.

Results

Demographics of patients with COVID-19

A total of 28 patients with COVID-19 were classified into the NSCP group, while 70 patients were classified into the SCP group. When comparing SCPs and NSCPs, a substantial drop in oxygen saturation was found (P = 0.001).SCPs had a significantly worse survival rate (P = 0.004) than NSCPs. SCPs had a higher radiological severity grade than NSCPs (P = 0.017). Dyspnea was significantly worse in the SCP group compared with the NSCP group (P = 0.044) (Table 1).

Table 1 Demographic data of covid 19 patients
Full size table

Hematological and biochemical laboratory abnormalities in patientswithCOVID-19

The hemoglobin (Hb) levels in the SCP group were lower than in the NSCP group(P = 0.028). White blood cells (WBCs), neutrophils, CRP, ferritin and D-dimer were all considerably lower in the NSCP group than in the SCP (p < 0.001). However, it was found that the lymphocyte count in NSCPs was higher than in SCPs (P = 0.001). Between the NSCP and SCP groups, there were no significant variations in serum creatinine, serum alanine transaminase (ALT) and serum aspartate transaminase (SGOT)activities, serum albumin, plasma INR and platelets count (Table 2).

Table 2 Hematological parameters of COVID-19 patients groups
Full size table

Serum sTLR4 and serum sCD14 in patientswithCOVID-19

The SCP group showed a significant increase in both serum sTLR4 and sCD14 levels compared with the NSCP group (P = 0.01 and 0.017), respectively (Table 3 and Figs. 1 and 2).

Table 3 Serum sTLR4 and sCD14 levels in patients with COVID-19
Full size table
Fig. 1
figure 1

Comparison of serum sCD14 levels between severe and non-severe COVID-19 patients

Full size image
Fig. 2
figure 2

Comparison of serum sTLR4 levels between severe and non-severe COVID-19 patients STLR4: soluble toll like receptor 4

Full size image

Regression analysis

Binary regression analysis was performed to assess the risk of COVID-19 severity for demographic factors, hematological abnormalities, serum sTLR4 and serum sCD14 levels (Table 4). COVID-19 patients with a lower lymphocyte count were more likely to develop severe symptoms (P = 0.006) OR (4.02). Moreover, patients with COVID-19 who presented with lower O2 saturation ratios were at high risk for developing more severe symptoms (P < 0.001), OR(8.19). In addition, patients with higher circulating levels of sTLR4 (P = 0.010),OR(3.36) and sCD14 (P = 0.012), OR(3.38) were much more vulnerable to severe symptoms of the disease. (Table 4).

Table 4 Linear regression analysis for factors predicting the severity of COVID-19
Full size table

Diagnostic performance of serum sTLR4 and sCD14

The ROC curve analysis was employed to assess the prediction value of sTLR4 and sCD14 as markers of COVID-19 severity, which revealed moderate diagnostic performance as measured by the AUC for sTLR4 (AUC = 0.655,CI 95%) with sensitivity 27.16% and specificity 68.97% and sCD14 (AUC = 0.665,CI 95%) with sensitivity74.07% and specificity 50.00% (Fig. 3) (Tables 5, and 6).

Fig. 3
figure 3

ROC curve analysis for ability of serum sCD14 and sTLR4 for discrimination between patients with non severe and severe COVID-19 infection (AUC for sCD14 = 0.665 and for sTLR4 = 0.655)

Full size image
Table 5 Correlation of serum sCD14 and sTLR4 with age and laboratory parameters of patient swith COVID-19
Full size table
Table 6 Diagnostic value of the sTLR for differentiation between severe and non-severe COVID – 19 at a cut point of at a cut point of 1.305 pg/ml
Full size table

Relationships betweensTLR4 and sCD14 with laboratory parameters

Serum sTLR4 showed a strong positive correlation with neutrophil count (P = 0.045), WBC count (P = 0.004), lymphocyte count (P = 0.028), AST activity (P = 0.042) and serum sCD14 levels (P < 0.001, r = 0.823) (Table 7 and Fig. 4). Concerning serum sCD14, there was a substantial positive correlation between its serum levels and WBC count (P = 0.004), neutrophil count (P = 0.019), lymphocyte count (P = 0.016), AST activity (P = 0.020), ALT activity (P = 0.018) and serum sTLR4 (P < 0.001, r = 0.823) (Table 7 and Fig. 4).

Table 7 Diagnostic value of the CD14 for differentiation between severe and non-severe COVID – 19 at a cut point of at a cut point of 0.67 pg/ml
Full size table
Fig. 4
figure 4

Correlation between Serum CD14 and sTLR4 levels in covid19 patients

Full size image

Discussion

TLRs are a type of pattern recognition receptor that play an important function in the immune system of the host [18]. They play a key role in systemic inflammation by activating the MAPK/NFB signaling pathway, which results in cytokines production and the maintenance of chronic inflammation [19]. To counteract systemic inflammation caused by TLRS activation, sTLRs are released into the circulation from tissues and blood cells [20]. TLR4 in its soluble form suppresses TLR4-mediated signaling as well,it likely mediates this effect by interfering with receptor-ligand interactions [21]. sCD14, as a co receptor of TLR4 signaling on the other hand, is involved in controlling TLR4-induced cytokine release through directly binding LPS to alter TLRS signaling patterns [22].

Thus, the goal of the present study was to gain insight into the serum levels of sTLR4 and sCD14 in SCPs and NSCPs to assess their correlation with hematological abnormalities and to investigate their potential clinical utility as a clinical severity marker forCOVID-19 patients.To the best of our knowledge, this is the first study that evaluated the serum levels of sTLR4 as an endogenous negative regulator of TLR4 signaling in patients with COVID-19.

A number of hematological abnormalities were found in SCPs compared with NSCPs in the present study, including lymphopenia and low hemoglobin levels, hyperferritinemia, elevated serum LDH levels and raised circulating CRP levels. Furthermore, there was strong evidence of a specific coagulopathy risk in SCPs, as seen by the increased plasma D-dimer levels and a higher risk of thrombotic events.

The precise method by which COVID-19 lymphopenia develops is unknown, however it could be connected to lymphocyte expression of the main SARS-CoV-2 entry receptor, ACE2, and subsequent lymphoid death as a result of infection [23, 24]. This process may be aided by lymphocyte trafficking from the peripheral circulation to the lungs or other infection sites [25]. The neutrophilia reported in severe COVID-19 instances, on the other hand, can be related to a response to the cytokine storm, which has been linked to the disease's most severe symptoms [26]. Additionally, large increases were seen in the acute-phase markers ferritin and CRP. Numerous studies have found that biomarkers such as ferritin and CRP are positively correlated with elevated pro-inflammatory cytokines and are linked to COVID-19 severity and mortality [27, 28]. The increased risk of coagulopathy in SCPs was also detected in the current study, as reflected by higher plasma D-dimer levels compared with NSCPs. This finding was consistent with prior studies that indicated that a rise in D-dimer levels is linked to the development of severe disease and in-hospital mortality in patients withCOVID-19 [25]. Various factors contribute to the enhanced coagulopathy seen in severe patients, including direct endothelial injury from SARS-CoV-2 or immune cells [25], cytokine-induced coagulation cascade activation [29] and an increase in acute-phase pro-coagulants, including factor VIII and fibrinogen [25].

Lower hemoglobin levels were associated with hyperferritinemia and elevated LDH levels in SCPs which are major predictors of mortality [30, 31]. Activated innate immune response, which restricts iron availability during infections is the susceptible mechanism that can also lead to anemia, which in turn reduces oxygen delivery to the tissue and may thus play an important role in the development of multi-organ failure. On the other hand, increased ferritin levelsas acute phase protein in SCPs could be attributed to a robust inflammatory response [32, 33]. In addition, the higher levels of LDH in the examined SCPs could be attributed to severe infections that may result in tissue damageand cells apoptosis mediated by cytokines and the release of LDH.As LDH (isozyme 3) is found in lung tissue, patients with severe COVID-19 infections may discharge more LDH into the bloodstream, as a severe form of interstitial pneumonia [34].

The most important novel finding in the present study was the significantly elevated levels of serum sTLR4 and sCD14 inthe SCP group compared with the NSCP group. This finding was in line with previous research, which found that sTLRs are released into the circulation from tissues and blood cells, and their levels rise during infections and inflammatory diseases [35, 36]. TenOeveret al [36] reported rapid elevation of sTLR4 in plasma after LPS treatment and showed that this rapid increase is a feedback mechanism to counteract TLR4 signaling activation. Furthermore, STLR4 is proposed to create a complex with myeloid differentiation factor 2(MD-2)and prevent the TLR4-MD-2 complex from forming, which is required for ligand binding and thus inhibits TLR signaling [36]. In addition, sTLR4 may interfere with LPS/TLR4 signaling by interacting with CD14 and/or LPS binding protein, both of which are required for ligand binding with TLR4 [10]. Moreover, the current study found a substantial positive association between sTLR4 and sCD14,leukocytosis, lymphopenia and neutrophilia, all of which are strong indicators of COVID-19 severity. This positive correlation between sCD14, sTLR4 and both lymphopenia andneutophilia may be attributed to the direct expression of TLRs on the surface of these cells and the impact of these receptor signaling on controlling their effector functions [5].

Furthermore, ROC analysis revealed that sTLR4 was a predictive marker for identifying SCPs and NSCPs. All of these data supported the concept that sTLR4 plays a compensatory role in reducing systemic inflammation in highly infected COVID-19 patients. The current study also found that SCPs had higher median blood levels of serum sCD14 than NSCPs, which was consistent with a recent study that detected higher serum sCD14 levels in patients with COVID-19 admitted to hospital (37).The elevated levels of sCD14 can be attributed to the compensatory role of sCD14 as a negative regulator of TLR signaling [37,38,39].

Conclusion

Finally, it can be concluded that sTLR4and sCD14, as endogenous negative regulators of TLR4 signaling, may be disease severity markers with moderate sensitivity for patients with COVID-19. Future research is needed to validate these results on large patients’ cohort and to confirm the predictive significance of these regulators as a promising target for immunotherapy in patients with COVID-19 infection.

Study limitations

Despite this study provides preliminary evidence that sTLR4 and sCD14 may serve as markers of COVID-19 severity. Some limitations should be presented as follow

  • - Single timepoint measurement of sTLR4/sCD14 limits ability to assess relationship with disease progression.- The patient population lacks diversity—conducted at a single center in Egypt. Results may not generalize to other populations. In other words, Small sample size from a single center limits generalizability widely.

  • - Lack of longitudinal follow-up data. No validation cohort to confirm findings.- No healthy control group for comparison of baseline TLR levels.- Potential confounding factors are not fully addressed in the analysis, like age and co-morbidities.- Underlying conditions that could affect TLR levels are excluded but these are important comorbidities for COVID-19.- It would be better if the cases number were more than 150 cases.—Specifics of patient treatment regimens are not reported.- Mechanistic/functional relationship between TLR levels and COVID-19 severity not fully established. Complementary functional studies are needed to delineate the mechanistic and causal relationships between sTLR4/sCD14 levels and COVID-19 disease severity that are lacking in this observational clinical study. This will better establish these markers as prognostic biomarkers and therapeutic targets.

Availability of data and materials

The authors will not share their data as these data confined to the participants in this research only The data that support the findings of this study are available from the corresponding author upon reasonable request.

Abbreviations

sTLR4:

Soluble toll like receptor 4

sCD14:

Soluble cd14

TLR4:

Toll like receptor 4

References

  1. World health organization. Coronavirus disease (COVID-2019) situation reports. 2020.

  2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.

    Article  CAS  Google Scholar 

  3. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.

    Article  CAS  PubMed  Google Scholar 

  4. O’Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in toll-like receptor signaling. Nat Rev Immunol. 2007;7(5):353–64. https://doi.org/10.1038/nri2079.

    Article  CAS  PubMed  Google Scholar 

  5. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821–32. https://doi.org/10.1016/j.cell.2010.01.040.

    Article  CAS  PubMed  Google Scholar 

  6. Dekleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovascular Res. 2003;60(1):58–67. https://doi.org/10.1016/S0008-6363(03)00348-1.

    Article  CAS  Google Scholar 

  7. Fu J, Zhou B, Zhang L, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Mol Biol Rep. 2020;47(6):4383–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Elkammah M, Gowily A, Okda T, Houssen M. Serum soluble toll-like receptor 4 and the risk of hepatocellular carcinoma in hepatitis C virus patients. Contemp Oncol (Pozn). 2020;24(4):216–20.

    CAS  PubMed  Google Scholar 

  9. Zunt S, Burton L, Goldblatt L, Dobbins M, Srinivasan M. Soluble forms of toll-like receptor 4 are present in human saliva and modulate tumour necrosis factor-a secretion by macrophage-like cells. Clin Exp Immunol. 2009;156:285–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. -Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikacharoen T, Yoshikai Y. Cutting edge: naturally occurring soluble form of mouse toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol. 2000;165:6682–6.

    Article  CAS  PubMed  Google Scholar 

  11. Fakhry N, Gowily A, Okda T, Houssen M. Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma. Contemp Oncol (Pozn). 2020;24(3):157–62.

    CAS  PubMed  Google Scholar 

  12. Bas S, Gauthier BR, Spenato U, et al. CD14 is an acutephase protein. J Immunol. 2004;172:4470–9.

    Article  CAS  PubMed  Google Scholar 

  13. Vercelli D, Baldini M, Stern D, et al. CD14: a bridge between innate immunity and adaptive IgE responses. J Endotoxin Res. 2001;7:45–8.

    Article  CAS  PubMed  Google Scholar 

  14. Yu B, Hailman E, Wright SD. Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. J Clin Invest. 1997;99:315–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. -Ward C, Walters EH, Zheng L, et al. Increased soluble CD14 in bronchoalveolar lavage fluid of stable lung transplant recipients. Eur Respir J. 2002;19:472–8.

    Article  CAS  PubMed  Google Scholar 

  16. Zdolsek HA, Jenmalm MC. Reduced levels of soluble CD14 in atopic children. Clin Exp Allergy. 2004;34:532–9.

    Article  CAS  PubMed  Google Scholar 

  17. Rial J, Tuala M, Rivero-Calle E, et al. Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. Front Immunol. 2020;11(1648):1652.

    Google Scholar 

  18. -Qureshi ST, Larivie`re L, Leveque G, Clermont S, Moore KJ, Gros P. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J Exp Med. 1999;189:615–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang Y, Chen T, Han C, He D, Liu H, An H, et al. Lysosome-associatedsmallrab GTPase Rab7b negatively regulates TLR4 signaling in macrophagesby promoting lysosomal degradation of TLR4. Blood. 2007;110:962–71.

    Article  CAS  PubMed  Google Scholar 

  20. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1:135–45.

    Article  CAS  PubMed  Google Scholar 

  21. Kharashy G, Gowily A, Okda T, Houssen M. Association between serum soluble Tolllike receptor 2 and 4 and the risk of breast cancer. Mol Clin Oncol. 2021;14:38.

    Article  PubMed  Google Scholar 

  22. Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cellboundLPS to plasma lipoproteins. J Clin Invest. 2001;108:485–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:1–5.

    Article  Google Scholar 

  24. Chen Y, Feng Z, Diao B, et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. MedRxiv. 2020. https://doi.org/10.1101/2020.03.27.20045427.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell Infection andendotheliitis in COVID-19. Lancet. 2020;395:1417–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20:363–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortalityof adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. -Chen G, Wu D, Guo W, et al. Clinical and immunologic featuresin severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Connors J, Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.

    Article  CAS  PubMed  Google Scholar 

  30. -. Bennett TD, Hayward KN, Farris RW, Ringold S, Wallace CA, Brogan TV. Very high serum ferritin levels are associated with increased mortality and critical care in pediatric patients. PediatrCrit Care Med. 2011;12(6):e233–6236.

    Article  Google Scholar 

  31. Liu Z, Sun R, Li J, Cheng W, Li L. Relations of anemia with the all-cause mortality and cardiovascular mortality in general population: a meta-analysis. Am J Med Sci. 2019;358(3):191–9.

    Article  PubMed  Google Scholar 

  32. Kernan KF, Carcillo JA. Hyperferritinemia and inflammation. International immunology. 2017;29(9):401–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wessling-Resnick M. Crossing the iron gate: why and howtransferrin receptors mediate viral entry. Annu Rev Nutr. 2018;38:431–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ganz T. Anemia of inflammation. N Engl J Med. 2019;381(12):1148–57.

    Article  CAS  PubMed  Google Scholar 

  35. Wei F, Yang F, Li J, Zheng Y, Yu W, Yang L, Ren X. Soluble Toll-likereceptor 4 is a potential serum biomarker in non-small cell lung cancer. Oncotarget. 2016;7:40106–14.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ten Oever J, Kox M, Van de Veerdonk FL, et al. The discriminative capacity of soluble toll-like receptor (sTLR) 2 and sTLR4 in inflammatory diseases. BMC Immunol. 2014;15:1–55.

    Article  Google Scholar 

  37. Varki A, Angata T. Siglecs: the major subfamily of I-typelectins. Glycobiology. 2006;16:1R–27R.

    Article  CAS  PubMed  Google Scholar 

  38. Chen X, Doffek K, Sugg SL, Shilyansky J. Phosphatidylserineregulates the maturation of human dendritic cells. J Immunol. 2004;173:2985–94.

    Article  CAS  PubMed  Google Scholar 

  39. Beesley R, Keillor V, Rutherford M, Basheer F, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med. 2023;29:1760–74.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. This research did not receive any funding for interpretation in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Author information

Authors and Affiliations

  1. Biochemistry Department Faculty of Pharmacy Damanhour University, Damanhour, 22511, Egypt

    Maha E. Houssen

  2. Chest Medicine Department Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt

    Marwa O. Elmaria

  3. Department of Medical Microbiology and Immunology Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt

    Dina Badr & Rasha El-Mahdy

  4. Hematology Unit, Clinical Pathology Department Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt

    Mayada A. Ghannam & Metwaly Ibrahim Mortada

  5. Clinical Hematology, Department of Internal Medicine, Oncology Centre, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt

    Shaimaa El-Ashwah & May Denewer

Authors
  1. Maha E. Houssen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marwa O. Elmaria
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dina Badr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rasha El-Mahdy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mayada A. Ghannam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shaimaa El-Ashwah
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. May Denewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Metwaly Ibrahim Mortada
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MH carried out Conceptualization . MH carried out Data curation. MH, ME,DB RM MM,SA,MD participated in Interpretation of Data. MM and MG carried out immunoassay . MH Writing and editing  original  and last paper drafts. M.E. Patient selection and Investigation. All authors  read and approved the final manuscript.

Corresponding author

Correspondence to Maha E. Houssen.

Ethics declarations

Ethics approval and consent to participate

The study was authorized by the Ethical Committee of the Faculty of Medicine of Mansoura University (approval no. R.21.9.1450; Egypt).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Houssen, M.E., Elmaria, M.O., Badr, D. et al. Serum soluble toll-like receptor 4 and risk for clinical severity in COVID-19 patients. Pneumonia 16, 1 (2024). https://doi.org/10.1186/s41479-023-00121-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s41479-023-00121-9

Keywords

Pneumonia

ISSN: 2200-6133

Contact us